| Basal Cell Skin Cancer References 1. Kuijpers DI, Thissen MR, Neumann MH. Basal cell carcinoma: treatment options and prognosis, a scientific approach to a common malignancy. Am J Clin Dermatol 2002; 3:247–59. 2. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135:1177–83. 3. Braun RP, Klumb F, Girard C et al. Three-dimensional reconstruction of basal cell carcinomas. Dermatol Surg 2005; 31:562–6. 4. Breuninger H, Dietz K. Prediction of subclinical tumor infiltration in basal cell carcinoma. J Dermatol Surg Oncol 1991; 17:574–8. 5. Hendrix JD Jr, Parlette HL. Duplicitous growth of infiltrative basal cell carcinoma: analysis of clinically undetected tumor extent in a paired case–control study. Dermatol Surg 1996; 22:535–9. 6. Lo JS, Snow SN, Reizner GT et al. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol 1991; 24:715–19. 7. Ting PT, Kasper R, Arlette JP. Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg 2005; 9:10–15. 8. Costantino D, Lowe L, Brown DL. Basosquamous carcinoma – an under- recognized, high-risk cutaneous neoplasm: case study and review of the literature. J Plast Reconstr Aesthet Surg 2006; 59:424–8. 9. Gilbody JS, Aitken J, Green A. What causes basal cell carcinoma to be the commonest cancer? Aust J Public Health 1994; 18:218–21. 10. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994; 30:774–8. 11. Goodwin RG, Holme SA, Roberts DL. Variations in registration of skin cancer in the United Kingdom. Clin Exp Dermatol 2004; 29:328–30. 12. Diffey BL, Langtry JA. Skin cancer incidence and the ageing population. Br J Dermatol 2005; 153:679–80. 13. Gailani MR, Leffell DJ, Ziegler A et al. Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma. J Natl Cancer Inst 1996; 88:349– 54. 14. Roenigk RK, Ratz JL, Bailin PL, Wheeland RG. Trends in the presentation and treatment of basal cell carcinomas. J Dermatol Surg Oncol 1986; 12:860–5. 15. Lindgren G, Diffey BL. Basal cell carcinoma of the eyelids and solar ultraviolet radiation exposure. Br J Ophthalmol 1998; 82:1412–15. 16. Corona R, Dogliotti E, D'Errico M et al. Risk factors for basal cell carcinoma in a Mediterranean population: role of recreational sun exposure early in life. Arch Dermatol 2001; 137:1162–8. 17. Zak-Prelich M, Narbutt J, Sysa-Jedrzejowska A. Environmental risk factors predisposing to the development of basal cell carcinoma. Dermatol Surg 2004; 30: 248–52. 18. McNaughton SA, Marks GC, Green AC. Role of dietary factors in the development of basal cell cancer of the skin. Cancer Epidemiol Biomarkers Prev 2005; 14:1596–607. 19. Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med 2004; 6: 530–9. 20. Felder S, Rabinovitz H, Oliviero M, Kopf A. Dermoscopic differentiation of a superficial basal cell carcinoma and squamous cell carcinoma in situ. Dermatol Surg 2006; 32:423–5. 21. Bakis S, Irwig L, Wood G, Wong D. Exfoliative cytology as a diagnostic test for basal cell carcinoma: a meta-analysis. Br J Dermatol 2004; 150:829–36. 22. Williams LS, Mancuso AA, Mendenhall WM. Perineural spread of cutaneous squamous and basal cell carcinoma: CT and MR detection and its impact on patient management and prognosis. Int J Radiat Oncol Biol Phys 2001; 49:1061–9. 23. Leibovitch I, McNab A, Sullivan T et al. Orbital invasion by periocular basal cell carcinoma. Ophthalmology 2005; 112:717–23. 24. Meads SB, Greenway HT. Basal cell carcinoma associated with orbital invasion: clinical features and treatment options. Dermatol Surg 2006; 32:442–6. 25. Farley RL, Manolidis S, Ratner D. Aggressive basal cell carcinoma with invasion of the parotid gland, facial nerve, and temporal bone. Dermatol Surg 2006; 32:307–15. 26. Randle HW. Basal cell carcinoma: identification and treatment of the high-risk patient. Dermatol Surg 1996; 22:255–61. 27. Batra RS, Kelley LC. A risk scale for predicting extensive subclinical spread of nonmelanoma skin cancer. Dermatol Surg 2002; 28:107–12. 28. Bath-Hextall F, Perkins W, Bong J, Williams H. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007; 1:CD003412. 29. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol 2006; 45:489–98. 30. Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. Br J Dermatol 1999; 141:415–23. 31. Drake LA, Ceilley RI, Cornelison RL et al. Guidelines of care for basal cell carcinoma. The American Academy of Dermatology Committee on Guidelines of Care. J Am Acad Dermatol 1992; 26:117–20. 32. Backous DD, DeMonte F, El-Naggar A et al. Craniofacial resection for nonmelanoma skin cancer of the head and neck. Laryngoscope 2005; 115:931–7. 33. Smeets N. Little evidence available on treatments for basal cell carcinoma of the skin. Cancer Treat Rev 2005; 31:143–6. 34. Cataldo PA, Stoddard PB, Reed WP. Use of frozen section analysis in the treatment of basal cell carcinoma. Am J Surg 1990; 159:561–3. 35. Walker P, Hill D. Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australas J Dermatol 2006; 47:1–12. 36. Marchac D, Papadopoulos O, Duport G. Curative and aesthetic results of surgical treatment of 138 basal-cell carcinomas. J Dermatol Surg Oncol 1982; 8:379– 87. 37. Griffiths RW, Suvarna SK, Stone J. Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg 2005; 58:795–805. 38. Johnson TM, Tromovitch TA, Swanson NA. Combined curettage and excision: a treatment method for primary basal cell carcinoma. J Am Acad Dermatol 1991; 24:613– 17. 39. Chiller K, Passaro D, McCalmont T, Vin-Christian K. Efficacy of curettage before excision in clearing surgical margins of nonmelanoma skin cancer. Arch Dermatol 2000; 136:1327–32. 40. Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol 1987; 123:340–4. 41. Kimyai-Asadi A, Goldberg LH, Peterson SR et al. Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas. J Am Acad Dermatol 2005; 53:464–8. 42. Kimyai-Asadi A, Goldberg LH, Jih MH. Accuracy of serial transverse cross- sections in detecting residual basal cell carcinoma at the surgical margins of an elliptical excision specimen. J Am Acad Dermatol 2005; 53:469–74. 43. Kumar P, Orton CI, McWilliam LJ, Watson S. Incidence of incomplete excision in surgically treated basal cell carcinoma: a retrospective clinical audit. Br J Plast Surg 2000; 35:563–6. 44. Griffiths RW. Audit of histologically incompletely excised basal cell carcinomas: recommendations for management by re-excision. Br J Plast Surg 1999; 52:24–8. 45. Dieu T, Macleod AM. Incomplete excision of basal cell carcinomas: a retrospective audit. Aust NZ J Surg 2002; 72:219–21. 46. Sussman LA, Liggins DF. Incompletely excised basal cell carcinoma: a management dilemma? Aust NZ J Surg 1996; 66:276–8. 47. Wilson AW, Howsam G, Santhanam V et al. Surgical management of incompletely excised basal cell carcinomas of the head and neck. Br J Oral Maxillofac Surg 2004; 42:311–14. 48. Grabski WJ, Salasche SJ. Positive surgical excision margins of a basal cell carcinoma. Dermatol Surg 1998; 24:921–4. 49. Richmond JD, Davie RM. The significance of incomplete excision in patients with basal cell carcinoma. Br J Plast Surg 1987; 40:63–7. 50. Park AJ, Strick M, Watson JD. Basal cell carcinomas: do they need to be followed up? J R Coll Surg Edinb 1994; 39:109–11. 51. De Silva SP, Dellon AL. Recurrence rate of positive margin basal cell carcinoma: results of a five-year prospective study. J Surg Oncol 1985; 28:72–4. 52. Bieley HC, Kirsner RS, Reyes BA, Garland LD. The use of Mohs micrographic surgery for determination of residual tumor in incompletely excised basal cell carcinoma. J Am Acad Dermatol 1992; 26:754–6. 53. Liu FF, Maki E, Warde P et al. A management approach to incompletely excised basal cell carcinomas of skin. Int J Radiat Oncol Biol Phys 1991; 20:423–8. 54. Hauben DJ, Zirkin H, Mahler D, Sacks M. The biologic behavior of basal cell carcinoma: part I. Plast Reconstr Surg 1982; 69:103–9. 55. Robinson JK, Fisher SG. Recurrent basal cell carcinoma after incomplete resection. Arch Dermatol 2000; 136:1318–24. 56. Berlin J, Katz KH, Helm KF, Maloney ME. The significance of tumor persistence after incomplete excision of basal cell carcinoma. J Am Acad Dermatol 2002; 46:549– 53. 57. Koplin L, Zarem HA. Recurrent basal cell carcinoma: a review concerning the incidence, behavior, and management of recurrent basal cell carcinoma, with emphasis on the incompletely excised lesion. Plast Reconstr Surg 1980; 65:656–64. 58. Boulinguez S, Grison-Tabone C, Lamant L et al. Histological evolution of recurrent basal cell carcinoma and therapeutic implications for incompletely excised lesions. Br J Dermatol 2004; 151:623–6. 59. Rowe DE, Carroll RJ, Day CL. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 1989; 15: 424–31. 60. Burg G, Hirsch RD, Konz B, Braun-Falco O. Histographic surgery: accuracy of visual assessment of the margins of basal-cell epithelioma. J Dermatol Surg Oncol 1975; 1:21–4. 61. Mohs FE. Chemosurgery for skin cancer: fixed tissue and fresh tissue techniques. Arch Dermatol 1976; 112:211–15. 62. Lawrence CM. Mohs' micrographic surgery for basal cell carcinoma. Clin Exp Dermatol 1999; 24:130–3. 63. Nelson BR, Railan D, Cohen S. Mohs' micrographic surgery for nonmelanoma skin cancers. Clin Plast Surg 1997; 24:705–18. 64. Wennberg AM, Larko O, Stenquist B. Five-year results of Mohs' micrographic surgery for aggressive facial basal cell carcinoma in Sweden. Acta Derm Venereol (Stockh) 1999; 79:370–2. 65. Williford PM, Feldman SR. Surgery for basal-cell carcinoma of the face. Lancet 2004; 364:1732–3. 66. Rowe DE, Carroll RJ, Day CL Jr et al. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15:315–28. 67. Malhotra R, Huilgol SC, Huynh NT, Selva D. The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up. Ophthalmology 2004; 111:631–6. 68. Leibovitch I, Huilgol SC, Selva D et al. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol 2005; 53: 452–7. 69. Smeets NW, Kuijpers DI, Nelemans P et al. Mohs' micrographic surgery for treatment of basal cell carcinoma of the face – results of a retrospective study and review of the literature. Br J Dermatol 2004; 151:141–7. 70. Kimyai-Asadi A, Goldberg LH, Peterson SR et al. The incidence of major complications from Mohs micrographic surgery performed in office-based and hospital- based settings. J Am Acad Dermatol 2005; 53:628–34. 71. Cook JL, Perone JB. A prospective evaluation of the incidence of complications associated with Mohs micrographic surgery. Arch Dermatol 2003; 139:143–52. 72. Dobke MK, Miller SH. Tissue repair after Mohs surgery. A plastic surgeon's view. Dermatol Surg 1997; 23:1061–6. 73. Stein JM, Hrabovsky S, Schuller DE, Siegle RJ. Mohs micrographic surgery and the otolaryngologist. Am J Otolaryngol 2004; 25:385–93. 74. Inkster C, Ashworth J, Murdoch JR et al. Oculoplastic reconstruction following Mohs surgery. Eye 1998; 12:214–18. 75. Sciscio A, Stewart K, Grewal J et al. Periocular Mohs micrographic surgery: results of a dual-site day-surgery service. Orbit 2001; 20:209–15. 76. Breuninger H. Micrographic surgery of malignant skin tumors: a comparison of the frozen technique with paraffin sectioning. Facial Plast Surg 1997; 13:79–82. 77. der Plessis PJ, Dahl MG, Malcolm AJ et al. Mohs' surgery of periocular basal cell carcinoma using formalin-fixed sections and delayed closure. Br J Dermatol 1998; 138: 1003–8. 78. Skaria AM, Salomon D. Mohs' surgery of periocular basal cell carcinoma using formalin-fixed sections and delayed closure. Br J Dermatol 1999; 140:775. 79. Wong VA, Marshall JA, Whitehead KJ et al. Management of periocular basal cell carcinoma with modified en face frozen section controlled excision. Ophthal Plast Reconstr Surg 2002; 18:430–5. 80. Strong JW, Worsham GF, Hagerty RC. Peripheral in-continuity tissue examination: a modification of Mohs' micrographic surgery. Clin Plast Surg 2004; 31:1– 4. 81. Boztepe G, Hohenleutner S, Landthaler M, Hohenleutner U. Munich method of micrographic surgery for basal cell carcinomas: 5-year recurrence rates with life-table analysis. Acta Derm Venereol (Stockh) 2004; 84:218–22. 82. Bentkover SH, Grande DM, Soto H et al. Excision of head and neck basal cell carcinoma with a rapid, cross-sectional, frozen-section technique. Arch Facial Plast Surg 2002; 4:114–19. 83. Niederhagen B, von Lindern JJ, Berge S et al. Staged operations for basal cell carcinoma of the face. Br J Oral Maxillofac Surg 2000; 38:477–9. 84. Hsuan JD, Harrad RA, Potts MJ, Collins C. Small margin excision of periocular basal cell carcinoma: 5 year results. Br J Ophthalmol 2004; 88:358–60. 85. David DB, Gimblett ML, Potts MJ, Harrad RA. Small margin (2 mm) excision of peri-ocular basal cell carcinoma with delayed repair. Orbit 1999; 18:11–15. 86. Cook J, Zitelli JA. Mohs micrographic surgery: a cost analysis. J Am Acad Dermatol 1998; 39:698–703. 87. Bialy TL, Whalen J, Veledar E et al. Mohs micrographic surgery vs traditional surgical excision: a cost comparison analysis. Arch Dermatol 2004; 140:736–42. 88. Essers BA, Dirksen CD, Nieman FH et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Arch Dermatol 2006; 142:187–94. 89. Smeets NW, Krekels GA, Ostertag JU et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 2004; 364:1766–72. 90. Otley CC. Mohs' micrographic surgery for basal-cell carcinoma of the face. Lancet 2005; 365:1226–7. 91. Reymann F. 15 years' experience with treatment of basal cell carcinomas of the skin with curettage. Acta Derm Venereol (Stockh) 1985; 120 (Suppl.):56–9. 92. Sheridan AT, Dawber RP. Curettage, electrosurgery and skin cancer. Australas J Dermatol 2000; 41:19–30. 93. Edens BL, Bartlow GA, Haghighi P et al. Effectiveness of curettage and electrodesiccation in the removal of basal cell carcinoma. J Am Acad Dermatol 1983; 9: 383–8. 94. Barlow JO, Zalla MJ, Kyle A et al. Treatment of basal cell carcinoma with curettage alone. J Am Acad Dermatol 2006; 54:1039–45. 95. McDaniel WE. Therapy for basal cell epitheliomas by curettage only. Further study. Arch Dermatol 1983; 119:901–3. 96. Spiller WF, Spiller RF. Treatment of basal cell epithelioma by curettage and electrodesiccation. J Am Acad Dermatol 1984; 11:808–14. 97. Kopf AW, Bart RS, Schrager D et al. Curettage-electrodesiccation treatment of basal cell carcinomas. Arch Dermatol 1977; 113:439–43. 98. Motley RJ, Gould DJ, Douglas WS, Simpson NB. Treatment of basal cell carcinoma by dermatologists in the United Kingdom. British Association of Dermatologists Audit Subcommittee and the British Society for Dermatological Surgery. Br J Dermatol 1995; 132:437–40. 99. Carlson KC, Connolly SM, Winkelmann RK. Basal cell carcinoma on the lower extremity. J Dermatol Surg Oncol 1994; 20:258–9. 100. Silverman MK, Kopf AW, Grin CM et al. Recurrence rates of treated basal cell carcinomas. Part 2: curettage-electrodesiccation. J Dermatol Surg Oncol 1991; 17: 720–6. 101. Salasche SJ. Curettage and electrodesiccation in the treatment of midfacial basal cell epithelioma. J Am Acad Dermatol 1983; 8:496–503. 102. Suhge d'Aubermont PC, Bennett RG. Failure of curettage and electrodesiccation for removal of basal cell carcinoma. Arch Dermatol 1984; 120:1456– 60. 103. Spencer JM, Tannenbaum A, Sloan L, Amonette RA. Does inflammation contribute to the eradication of basal cell carcinoma following curettage and electrodesiccation? Dermatol Surg 1997; 23:625–30. 104. Nouri K, Spencer JM, Taylor JR et al. Does wound healing contribute to the eradication of basal cell carcinoma following curettage and electrodesiccation? Dermatol Surg 1999; 25:183–7. 105. Wu JK, Oh C, Strutton G, Siller G. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas J Dermatol 2006; 47:46–8. 106. Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg 2006; 32:63–9. 107. Soler AM, Warloe T, Berner A, Giercksky KE. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol 2001; 145:467–71. 108. Nordin P, Stenquist B. Five-year results of curettage-cryosurgery for 100 consecutive auricular non-melanoma skin cancers. J Laryngol Otol 2002; 116:893–8. 109. Graham G. Statistical data on malignant tumors in cryosurgery: 1982. J Dermatol Surg Oncol 1983; 9:238–9. 110. Zacarian SA. Cryosurgery of cutaneous carcinomas. An 18 year study of 3,022 patients with 4,228 carcinomas. J Am Acad Dermatol 1983; 9:947–56. 111. Mallon E, Dawber R. Cryosurgery in the treatment of basal cell carcinoma. Assessment of one and two freeze-thaw cycle schedules. Dermatol Surg 1996; 22: 854–8. 112. Goncalves JC. Fractional cryosurgery. A new technique for basal cell carcinoma of the eyelids and periorbital area. Dermatol Surg 1997; 23:475–81. 113. Holt PJ. Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery. Br J Dermatol 1988; 119:231–40. 114. Giuffrida TJ, Jimenez G, Nouri K. Histologic cure of basal cell carcinoma treated with cryosurgery. J Am Acad Dermatol 2003; 49:483–6. 115. Kokoszka A, Scheinfeld N. Evidence-based review of the use of cryosurgery in treatment of basal cell carcinoma. Dermatol Surg 2003; 29:566–71. 116. Bernardeau K, Derancourt C, Cambie M et al. [Cryosurgery of basal cell carcinoma: a study of 358 patients]. Ann Dermatol Venereol 2000; 127:175–9. 117. Kuflik EG, Gage AA. The five-year cure rate achieved by cryosurgery for skin cancer. J Am Acad Dermatol 1991; 24:1002–4. 118. Kuflik EG. Cryosurgery for skin cancer: 30-year experience and cure rates. Dermatol Surg 2004; 30:297–300. 119. Jaramillo-Ayerbe F. Cryosurgery in difficult to treat basal cell carcinoma. Int J Dermatol 2000; 39:223–9. 120. Kuflik EG, Gage AA. Recurrent basal cell carcinoma treated with cryosurgery. J Am Acad Dermatol 1997; 37:82–4. 121. Buschmann W. A reappraisal of cryosurgery for eyelid basal cell carcinomas. Br J Ophthalmol 2002; 86:453–7. 122. Anders M, Sporl E, Krantz H et al. [Cryotherapy of malignant eyelid tumors]. Ophthalmologe 1995; 92:787–92. 123. Tuppurainen K. Cryotherapy for eyelid and periocular basal cell carcinomas: outcome in 166 cases over an 8-year period. Graefes Arch Clin Exp Ophthalmol 1995; 233:205–8. 124. Gunnarson G, Larko O, Hersle K. Cryosurgery of eyelid basal cell carcinomas. Acta Ophthalmol (Copenh) 1990; 68:241–5. 125. Wang I, Bendsoe N, Klinteberg CA et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144:832–40. 126. Thissen MR, Nieman FH, Ideler AH et al. Cosmetic results of cryosurgery vs. surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg 2000; 26:759–64. 127. Nouri K, Chang A, Trent JT, Jimenez GP. Ultrapulse CO2 used for the successful treatment of basal cell carcinomas found in patients with basal cell nevus syndrome. Dermatol Surg 2002; 28:287–90. 128. Stockfleth E, Trefzer U, Garcia-Bartels C et al. The use of toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol 2003; 149 (Suppl. 66):53–6. 129. Marks R, Gebauer K, Shumack S et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose–response trial. J Am Acad Dermatol 2001; 44:807–13. 130. Geisse JK, Rich P, Pandya A et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47:390–8. 131. Geisse J, Caro I, Lindholm J et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle- controlled studies. J Am Acad Dermatol 2004; 50:722–33. 132. Schulze HJ, Cribier B, Requena L et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle- controlled phase III study in Europe. Br J Dermatol 2005; 152:939–47. 133. Gollnick H, Barona CG, Frank RG et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2- year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol 2005; 15:374–81. 134. Shumack S, Robinson J, Kossard S et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002; 138:1165–71. 135. Eigentler TK, Kamin A, Weide BM et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low risk nodular basal cell carcinoma. J Am Acad Dermatol 2007; 57:616–21. 136. Vidal D, Matias-Guiu X, Alomar A. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol 2007; 143:266–8. 137. Sterry W, Ruzicka T, Herrera E et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low- frequency dosing with and without occlusion. Br J Dermatol 2002; 147:1227–36. 138. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg 2000; 26:577–8. 139. Stockfleth E, Ulrich C, Hauschild A et al. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol 2002; 12:569–72. 140. Micali G, De Pasquale R, Caltabiano R et al. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report. J Dermatolog Treat 2002; 13:123–7. 141. Nikkels AF, Pierard-Franchimont C, Nikkels-Tassoudji N et al. Photodynamic therapy and imiquimod immunotherapy for basal cell carcinomas. Acta Clin Belg 2005; 60:227–34. 142. Morton CA, Brown SB, Collins S et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 2002; 146:552–67. 143. Varma S, Wilson H, Kurwa HA et al. Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br J Dermatol 2001; 144:567–74. 144. Clark C, Bryden A, Dawe R et al. Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatol Photoimmunol Photomed 2003; 19:134–41. 145. Kuijpers D, Thissen MR, Thissen CA, Neumann MH. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol 2006; 5:642–5. 146. Braathen LR, Szeimies R-M, Basset-Seguin N et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer. An international consensus. J Am Acad Dermatol 2007; 56:125–43. 147. Rhodes LE, de Rie M, Enström Y et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Results of a multicenter randomized prospective trial. Arch Dermatol 2004; 140:17–23. 148. Rhodes LE, de Rie MA, Leifsdottir R et al. Five year follow-up of a randomized, prospective trial of methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007; 143:1131–6. 149. Horn M, Wolf P, Wulf HC et al. Topical methyl aminolevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol 2003; 149:1242–9. 150. Vinciullo C, Elliott T, Francis D et al. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. Br J Dermatol 2005; 152:765–72. 151. Oseroff AR, Shieh S, Frawley NP et al. Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy. Arch Dermatol 2005; 141:60–7. 152. Itkin A, Gilchrest BA. delta-Aminolevulinic acid and blue light photodynamic therapy for the treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. Dermatol Surg 2004; 30:1054–61. 153. Morton CA. Methyl aminolevulinate (Metfix) photodynamic therapy – practical pearls. J Dermatolog Treat 2003; 14 (Suppl. 3):23–6. 154. Al-Othman MO, Mendenhall WM, Amdur RJ. Radiotherapy alone for clinical T4 skin carcinoma of the head and neck with surgery reserved for salvage. Am J Otolaryngol 2001; 22:387–90. 155. Rio E, Bardet E, Ferron C et al. Interstitial brachytherapy of periorificial skin carcinomas of the face: a retrospective study of 97 cases. Int J Radiat Oncol Biol Phys 2005; 63:753–7. 156. Guix B, Finestres F, Tello J et al. Treatment of skin carcinomas of the face by high-dose-rate brachytherapy and custom-made surface molds. Int J Radiat Oncol Biol Phys 2000; 47:95–102. 157. Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys 2004; 60:406– 11. 158. Childers BJ, Goldwyn RM, Ramos D et al. Long-term results of irradiation for basal cell carcinoma of the skin of the nose. Plast Reconstr Surg 1994; 93:1169–73. 159. Caccialanza M, Piccinno R, Grammatica A. Radiotherapy of recurrent basal and squamous cell skin carcinomas: a study of 249 re-treated carcinomas in 229 patients. Eur J Dermatol 2001; 11:25–8. 160. Finizio L, Vidali C, Calacione R et al. What is the current role of radiation therapy in the treatment of skin carcinomas? Tumori 2002; 88:48–52. 161. Caccialanza M, Piccinno R, Moretti D, Rozza M. Radiotherapy of carcinomas of the skin overlying the cartilage of the nose: results in 405 lesions. Eur J Dermatol 2003; 13:462–5. 162. Huynh NT, Veness MJ. Basal cell carcinoma of the lip treated with radiotherapy. Australas J Dermatol 2002; 43:15–19. 163. Silva JJ, Tsang RW, Panzarella T et al. Results of radiotherapy for epithelial skin cancer of the pinna: the Princess Margaret Hospital experience, 1982–1993. Int J Radiat Oncol Biol Phys 2000; 47:451–9. 164. Morrison WH, Garden AS, Ang KK. Radiation therapy for nonmelanoma skin carcinomas. Clin Plast Surg 1997; 24:719–29. 165. Zagrodnik B, Kempf W, Seifert B et al. Superficial radiotherapy for patients with basal cell carcinoma; recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. Cancer 2003; 98:2708–14. 166. Caccialanza M, Piccinno R, Kolesnikova L, Gnecchi L. Radiotherapy of skin carcinomas of the pinna: a study of 115 lesions in 108 patients. Int J Dermatol 2005; 44:513–17. 167. Avril MF, Auperin A, Margulis A et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 1997; 76:100–6. 168. Hall VL, Leppard BJ, McGill J et al. Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol 1986; 37:33–4. 169. Petit JY, Avril MF, Margulis A et al. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast Reconstr Surg 2000; 105:2544–51. 170. Caccialanza M, Percivalle S, Piccinno R. Possibility of treating basal cell carcinomas of nevoid basal cell carcinoma syndrome with superficial X-ray therapy. Dermatology 2004; 208:60–3. 171. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000; 136:1524–30. 172. Veien K, Veien NK. Risk of developing subsequent nonmelanoma skin cancers. Arch Dermatol 2001; 137:1251. 173. Levi F, Randimbison L, Maspoli M et al. High incidence of second basal cell skin cancers. Int J Cancer 2006; 119:1505–7. 174. van Iersel CA, van de Velden HV, Kusters CD et al. Prognostic factors for a subsequent basal cell carcinoma: implications for follow up. Br J Dermatol 2005; 153: 1078–80. 175. Ramachandran S, Fryer AA, Smith AG et al. Basal cell carcinoma. Cancer 2000; 89:1012–18. 176. Lear JT, Smith AG, Bowers B et al. Truncal tumor site is associated with high risk of multiple basal cell carcinoma and is influenced by glutathione S-transferase, GSTT1, and cytochrome P450, CYP1A1 genotypes, and their interaction. J Invest Dermatol 1997; 108:519–22. 177. Ramachandran S, Fryer AA, Smith A et al. Cutaneous basal cell carcinomas: distinct host factors are associated with the development of tumors on the trunk and head and neck. Cancer 2001; 92:354–8. 178. Mc Loone NM, Tolland J, Walsh M, Dolan OM. Follow up of basal cell carcinomas: an audit of current practice. J Eur Acad Dermatol Venereol 2006; 20:698– 701. 179. Bower CP, Lear JT, de Berker DA. Basal cell carcinoma follow-up practices by dermatologists: a national survey. Br J Dermatol 2001; 145:949–56. 180. Griffiths CEM. The British Association of Dermatologists guidelines for the management of skin disease. Br J Dermatol 1999; 141:396–7. |
| Aesthetic Medicine Today |
 | |  | |  | |  | |  | |  |
 | |  | |  | |  | |  | |  |
 | |  | |  |